vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and SOUNDHOUND AI, INC. (SOUN). Click either name above to swap in a different company.

SOUNDHOUND AI, INC. is the larger business by last-quarter revenue ($55.1M vs $33.4M, roughly 1.6× Ginkgo Bioworks Holdings, Inc.). On growth, SOUNDHOUND AI, INC. posted the faster year-over-year revenue change (59.4% vs -23.8%). SOUNDHOUND AI, INC. produced more free cash flow last quarter ($-22.3M vs $-47.7M). Over the past eight quarters, SOUNDHOUND AI, INC.'s revenue compounded faster (117.9% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

SoundHound AI, Inc. is an American music and speech recognition company based in Santa Clara, California. It was originally founded as Melodis in 2005 before rebranding to SoundHound Inc. in 2010, and SoundHound AI in 2022.

DNA vs SOUN — Head-to-Head

Bigger by revenue
SOUN
SOUN
1.6× larger
SOUN
$55.1M
$33.4M
DNA
Growing faster (revenue YoY)
SOUN
SOUN
+83.2% gap
SOUN
59.4%
-23.8%
DNA
More free cash flow
SOUN
SOUN
$25.4M more FCF
SOUN
$-22.3M
$-47.7M
DNA
Faster 2-yr revenue CAGR
SOUN
SOUN
Annualised
SOUN
117.9%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DNA
DNA
SOUN
SOUN
Revenue
$33.4M
$55.1M
Net Profit
$40.1M
Gross Margin
47.9%
Operating Margin
-211.9%
77.3%
Net Margin
72.8%
Revenue YoY
-23.8%
59.4%
Net Profit YoY
115.5%
EPS (diluted)
$-1.41
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
SOUN
SOUN
Q4 25
$33.4M
$55.1M
Q3 25
$38.8M
$42.0M
Q2 25
$49.6M
$42.7M
Q1 25
$48.3M
$29.1M
Q4 24
$43.8M
$34.5M
Q3 24
$89.0M
$25.1M
Q2 24
$56.2M
$13.5M
Q1 24
$37.9M
$11.6M
Net Profit
DNA
DNA
SOUN
SOUN
Q4 25
$40.1M
Q3 25
$-80.8M
$-109.3M
Q2 25
$-60.3M
$-74.7M
Q1 25
$-91.0M
$129.9M
Q4 24
$-258.6M
Q3 24
$-56.4M
$-21.8M
Q2 24
$-217.2M
$-37.3M
Q1 24
$-165.9M
$-33.0M
Gross Margin
DNA
DNA
SOUN
SOUN
Q4 25
47.9%
Q3 25
42.6%
Q2 25
39.0%
Q1 25
36.5%
Q4 24
39.9%
Q3 24
48.6%
Q2 24
63.0%
Q1 24
59.7%
Operating Margin
DNA
DNA
SOUN
SOUN
Q4 25
-211.9%
77.3%
Q3 25
-231.8%
-275.6%
Q2 25
-132.1%
-182.9%
Q1 25
-184.1%
Q4 24
-236.3%
-744.2%
Q3 24
-62.0%
-134.6%
Q2 24
-396.7%
-163.3%
Q1 24
-469.1%
-246.1%
Net Margin
DNA
DNA
SOUN
SOUN
Q4 25
72.8%
Q3 25
-207.9%
-259.9%
Q2 25
-121.6%
-175.1%
Q1 25
-188.2%
446.1%
Q4 24
-748.6%
Q3 24
-63.3%
-86.7%
Q2 24
-386.4%
-277.2%
Q1 24
-437.3%
-284.7%
EPS (diluted)
DNA
DNA
SOUN
SOUN
Q4 25
$-1.41
$-0.13
Q3 25
$-1.45
$-0.27
Q2 25
$-1.10
$-0.19
Q1 25
$-1.68
$0.31
Q4 24
$-1.91
$-0.75
Q3 24
$-1.08
$-0.06
Q2 24
$-4.23
$-0.11
Q1 24
$-3.32
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
SOUN
SOUN
Cash + ST InvestmentsLiquidity on hand
$422.6M
$248.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$463.8M
Total Assets
$1.1B
$688.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
SOUN
SOUN
Q4 25
$422.6M
$248.5M
Q3 25
$495.5M
$268.9M
Q2 25
$559.4M
$230.3M
Q1 25
$325.3M
$245.8M
Q4 24
$561.6M
$198.2M
Q3 24
$616.2M
$135.6M
Q2 24
$730.4M
$200.2M
Q1 24
$840.4M
$211.7M
Total Debt
DNA
DNA
SOUN
SOUN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
$85.5M
Stockholders' Equity
DNA
DNA
SOUN
SOUN
Q4 25
$508.6M
$463.8M
Q3 25
$559.8M
$399.2M
Q2 25
$613.0M
$359.8M
Q1 25
$647.4M
$397.0M
Q4 24
$716.1M
$182.7M
Q3 24
$797.9M
$296.0M
Q2 24
$833.1M
$223.9M
Q1 24
$987.3M
$155.5M
Total Assets
DNA
DNA
SOUN
SOUN
Q4 25
$1.1B
$688.2M
Q3 25
$1.2B
$702.2M
Q2 25
$1.2B
$579.5M
Q1 25
$1.3B
$587.5M
Q4 24
$1.4B
$554.0M
Q3 24
$1.5B
$499.7M
Q2 24
$1.6B
$266.7M
Q1 24
$1.6B
$287.4M
Debt / Equity
DNA
DNA
SOUN
SOUN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
SOUN
SOUN
Operating Cash FlowLast quarter
$-47.7M
$-21.9M
Free Cash FlowOCF − Capex
$-47.7M
$-22.3M
FCF MarginFCF / Revenue
-142.8%
-40.4%
Capex IntensityCapex / Revenue
0.0%
0.7%
Cash ConversionOCF / Net Profit
-0.55×
TTM Free Cash FlowTrailing 4 quarters
$-99.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
SOUN
SOUN
Q4 25
$-47.7M
$-21.9M
Q3 25
$-31.6M
$-32.7M
Q2 25
$-40.3M
$-24.5M
Q1 25
$-51.5M
$-19.2M
Q4 24
$-42.4M
$-33.1M
Q3 24
$-103.5M
$-35.3M
Q2 24
$-84.4M
$-18.5M
Q1 24
$-89.3M
$-21.9M
Free Cash Flow
DNA
DNA
SOUN
SOUN
Q4 25
$-47.7M
$-22.3M
Q3 25
$-32.8M
Q2 25
$-40.3M
$-24.7M
Q1 25
$-59.1M
$-19.3M
Q4 24
$-56.1M
$-33.2M
Q3 24
$-118.6M
$-35.5M
Q2 24
$-111.4M
$-18.7M
Q1 24
$-96.0M
$-22.0M
FCF Margin
DNA
DNA
SOUN
SOUN
Q4 25
-142.8%
-40.4%
Q3 25
-78.1%
Q2 25
-81.2%
-57.8%
Q1 25
-122.4%
-66.4%
Q4 24
-128.0%
-96.1%
Q3 24
-133.2%
-141.6%
Q2 24
-198.2%
-139.1%
Q1 24
-252.9%
-190.2%
Capex Intensity
DNA
DNA
SOUN
SOUN
Q4 25
0.0%
0.7%
Q3 25
0.0%
0.4%
Q2 25
0.1%
0.4%
Q1 25
15.8%
0.6%
Q4 24
31.3%
0.2%
Q3 24
16.9%
0.9%
Q2 24
48.1%
1.8%
Q1 24
17.7%
0.9%
Cash Conversion
DNA
DNA
SOUN
SOUN
Q4 25
-0.55×
Q3 25
Q2 25
Q1 25
-0.15×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

SOUN
SOUN

Hosted Services$37.7M68%
Licensing$12.6M23%
Professional Service$4.6M8%

Related Comparisons